The overall goal of the Experimental Therapeutics (ET) Program is the development of novel mechanism-driven anticancer therapies through an improved understanding of molecular pathways in normal cells and cancer cells and insights into mechanisms involved in drug resistance. To achieve this goal, the Program is organized into three interacting (interactive) research themes that span the spectrum of basic, translational and clinical science: Angiogenesis and Metastasis, Cell Survival and Drug Resistance, and Gene expression and Molecular Targets, In addition to these themes, the ET program has two overarching missions. First, to be the conduit for bringing scientific findings from other CCSG programs into the clinic. As such, the Phase I and ET Drug Development expertise provides an Institute-wide resource for drug discovery methods, preclinical efficacy studies, IND-enabling toxicology, IND submission support, PK/PD modeling, and clinical trial conduct and management. Secondly, the ET Program is committed to training the next generation of clinician-scientists with expertise in all phases of drug development. The Program is co-led by Drs. Alex Adjei, and William Cance. Dr. Adjei is an internationally recognized clinician scientist with expertise in drug development, phase l/ll clinical trials of novel cancer agents and lung cancer. As the director of the Phase I unit, his leadership has been instrumental in building the drug development team. His research interests are in targeting cell survival pathways for cancer therapy in lung cancer. Dr. Cance is a highly regarded cancer surgeon and translational scientist with long-standing interests in angiogenesis and tumor metastasis. He has an ROl-funded program evaluating FAK inhibitors for cancer therapy. The complementary expertise of the leadership team facilitates the integration of basic, translational and clinical science by providing venues to promote discussion of research, formation of basic science-clinical partnerships, and providing guidance to membership for available research funding. The Program consists of 25 members from 7 departments. 541 publications are the product of ET members (2008-2013), with 23% of the publications as intra-programmatic and 22% inter-programmatic. 34 publications were in journals with Impact Factor >10. The ET Program has translated recent preclinical findings into 12 ongoing clinical trials. There were 326 patients enrolled to treatment trials in CY2012 compared with 453 patients in CY2008. Current annual total peer-reviewed Program funding is $10.3M, of which $9.3M is from NCI, and the total extramural research funding is $14.4M.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Miller, James A; Harris, Kassem; Roche, Charles et al. (2018) Sarcopenia is a predictor of outcomes after lobectomy. J Thorac Dis 10:432-440
Fenstermaker, Robert A; Figel, Sheila A; Qiu, Jingxin et al. (2018) Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo. Clin Cancer Res 24:2642-2652
Bhat, Tariq A; Kalathil, Suresh Gopi; Bogner, Paul N et al. (2018) Secondhand Smoke Induces Inflammation and Impairs Immunity to Respiratory Infections. J Immunol 200:2927-2940
Merzianu, Mihai; Groman, Adrienne; Hutson, Alan et al. (2018) Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada: A Multicenter Study. Am J Clin Pathol 150:393-405
Qin, Bo; Llanos, Adana A M; Lin, Yong et al. (2018) Validity of self-reported weight, height, and body mass index among African American breast cancer survivors. J Cancer Surviv 12:460-468
Qiao, Guanxi; Chen, Minhui; Bucsek, Mark J et al. (2018) Adrenergic Signaling: A Targetable Checkpoint Limiting Development of the Antitumor Immune Response. Front Immunol 9:164
Kumar, Sandeep; Inigo, Joseph R; Kumar, Rahul et al. (2018) Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells. Cancer Lett 413:82-93
Liu, Chunhong; Yu, Tao; Xing, Zhuo et al. (2018) Triplications of human chromosome 21 orthologous regions in mice result in expansion of megakaryocyte-erythroid progenitors and reduction of granulocyte-macrophage progenitors. Oncotarget 9:4773-4786
Muramatsu, Masashi; Akakura, Shin; Gao, Lingqiu et al. (2018) SSeCKS/Akap12 suppresses metastatic melanoma lung colonization by attenuating Src-mediated pre-metastatic niche crosstalk. Oncotarget 9:33515-33527
Gurova, Katerina; Chang, Han-Wen; Valieva, Maria E et al. (2018) Structure and function of the histone chaperone FACT - Resolving FACTual issues. Biochim Biophys Acta Gene Regul Mech :

Showing the most recent 10 out of 1555 publications